# Jagsonpal Ser (NSE: JAGSNPHARM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/JAGSNPHARM · Pivot · prices to 22 Oct 2026

Jagsonpal Ser (NSE: JAGSNPHARM) closed at ₹211.40 on 22 Oct 2026, down 3.25% on the day. With a market capitalisation of ₹1,392 Cr, it ranks 1295th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 33.4× trailing earnings, against a return on equity of −4.4% in FY25. Over the past year the share price has fallen 0.2%. Its 52-week range is ₹155.00 (22 Jan 2026) to ₹264.50 (30 Jun 2026); the last close is 20.1% below the high. Promoters held 69.05% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹211.40 |
| Market cap | ₹1,392 Cr |
| P/E (trailing) | 33.4 |
| ROE | −4.4% (FY25) |
| ROCE | −8.3% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹264.50 (30 Jun 2026) |
| 52-week low | ₹155.00 (22 Jan 2026) |
| 1-year return | −0.2% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | −₹1 Cr |
| FY24 | ₹1 Cr | ₹0 Cr |
| FY23 | ₹0 Cr | −₹0 Cr |
| FY22 | ₹0 Cr | −₹0 Cr |
| FY21 | ₹0 Cr | ₹0 Cr |
| FY20 | −₹1 Cr | −₹1 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 69.05%
- Foreign institutions: 2.30%
- Domestic institutions: 0.62%
- Non-institutions: 28.03%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Suraksha Diagnostic](https://app.pivotnow.in/stock/SURAKSHA) | ₹289.60 | ₹1,508 Cr | 46.9 | — |
| [Astec LifeSciences](https://app.pivotnow.in/stock/ASTEC) | ₹666.40 | ₹1,485 Cr | — | — |
| [Amrutanjan Health Care](https://app.pivotnow.in/stock/AMRUTANJAN) | ₹499.00 | ₹1,443 Cr | 24.9 | — |
| [Gujarat Kidney And Super Speciality](https://app.pivotnow.in/stock/GKSL) | ₹179.49 | ₹1,415 Cr | 72.1 | — |
| [TTK Healthcare](https://app.pivotnow.in/stock/TTKHLTCARE) | ₹989.70 | ₹1,398 Cr | 21.3 | — |
| [Fermenta Biotech](https://app.pivotnow.in/stock/FERMENTA) | ₹455.25 | ₹1,340 Cr | — | — |

## Questions and answers

### What is the share price of Jagsonpal Ser today?

Jagsonpal Ser (NSE: JAGSNPHARM) last closed at ₹211.40 on 22 Oct 2026. Its 52-week high is ₹264.50 and its 52-week low is ₹155.00.

### What is the market cap of Jagsonpal Ser?

Jagsonpal Ser's market capitalisation is ₹1,392 Cr (₹1,392 Cr) at the 22 Oct 2026 close, ranking 1295th among the NSE companies Pivot tracks.

### What is the P/E ratio of Jagsonpal Ser?

Jagsonpal Ser trades at a trailing P/E of 33.4. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 46.9.

### What is the ROE and ROCE of Jagsonpal Ser?

Return on equity was −4.4% in FY25 and return on capital employed was −8.3% in FY25 (standalone figures).

### Is Jagsonpal Ser a debt-free company?

Jagsonpal Ser is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### How has Jagsonpal Ser stock performed over the last year?

Jagsonpal Ser's share price has fallen 0.2% over the past year, −3.8% over three months and −7.2% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Jagsonpal Ser?

As of 30 Jun 2026: promoters 69.05%, foreign institutions 2.30%, domestic institutions 0.62%, non-institutions 28.03%.

### Who are Jagsonpal Ser's competitors?

The listed Pharma & Healthcare companies closest to Jagsonpal Ser by market cap are Suraksha Diagnostic, Astec LifeSciences, Amrutanjan Health Care, Gujarat Kidney And Super Speciality, TTK Healthcare and Fermenta Biotech.

### Is Jagsonpal Ser a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Jagsonpal Ser's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on JAGSNPHARM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.